Royal Philips (NYSE:PHG) said today that two of the company’s new Stellarex drug-coated balloons received FDA approval for the treatment of upper leg artery blockages.
The approval was for both de novo and restenotic lesions in upper leg arteries.
The Amsterdam-based company said the new low-dose (200 mm and 150 mm) balloons will be added to the Stellarex DCB portfolio to broaden options for treating peripheral artery disease in patients with a high risk of restenosis in the superficial femoral or popliteal arteries.
Get the full story at our sister site, Drug Delivery Business News.